Background. The expected value of sample information (EVSI) can help prioritize research but its application is hampered by computational infeasibility, especially for complex models. We investigated an approach by Strong and colleagues to estimate EVSI by applying generalized additive models (GAM) to results generated from a probabilistic sensitivity analysis (PSA). Methods. For 3 potential HIV prevention and treatment strategies, we estimated life expectancy and lifetime costs using the Cost-effectiveness of Preventing AIDS Complications (CEPAC) model, a complex patient-level microsimulation model of HIV progression. We fitted a GAM-a flexible regression model that estimates the functional form as part of the model fitting process-to the incremental net monetary benefits obtained from the CEPAC PSA. For each case study, we calculated the expected value of partial perfect information (EVPPI) using both the conventional nested Monte Carlo approach and the GAM approach. EVSI was calculated using the GAM approach. Results. For all 3 case studies, the GAM approach consistently gave similar estimates of EVPPI compared with the conventional approach. The EVSI behaved as expected: it increased and converged to EVPPI for larger sample sizes. For each case study, generating the PSA results for the GAM approach required 3 to 4 days on a shared cluster, after which EVPPI and EVSI across a range of sample sizes were evaluated in minutes. The conventional approach required approximately 5 weeks for the EVPPI calculation alone. Conclusion. Estimating EVSI using the GAM approach with results from a PSA dramatically reduced the time required to conduct a computationally intense project, which would otherwise have been impractical. Using the GAM approach, we can efficiently provide policy makers with EVSI estimates, even for complex patient-level microsimulation models. Keywords EVSI, GAM, HIV, value of information Date received: November 21, 2016; accepted: July 26, 2017 Computer simulation models of disease are used to compare the expected incremental net benefits of alternative strategies based on a set of input parameters; however, these parameters are rarely known with certainty. The expected value of perfect information (EVPI) and the expected value of partial perfect information (EVPPI) represent the economic benefit of eliminating uncertainty in all parameters or a subset of parameters. The EVPI targets all model parameters whereas the
Computer simulation models of disease are used to compare the expected incremental net benefits of alternative strategies based on a set of input parameters; however, these parameters are rarely known with certainty. The expected value of perfect information (EVPI) and the expected value of partial perfect information (EVPPI) represent the economic benefit of eliminating uncertainty in all parameters or a subset of parameters. The EVPI targets all model parameters whereas the EVPPI relates to a specified subset. As this would require a study of infinite sample size, a more practical metric is the expected value of sample information (EVSI), which represents the benefit of reducing parameter uncertainty by collecting study outcomes in a finite sample, as done in a clinical trial. EVSI can determine whether further research will demonstrate good value and which study designs and sizes will be optimal.
The conventional approach to EVPPI and EVSI uses a nested Monte Carlo procedure. 1 While considered the gold standard, this conventional approach is computationally intensive, especially for complex patient-level microsimulation models. Though alternative methods have recently been developed to facilitate and expedite EVPPI and EVSI estimations, [2] [3] [4] [5] [6] [7] no practical applications to a complex model exist to support them. To address this research gap, we applied one of these methods, a flexible regression approach developed by Strong and others, 5 to 3 different case studies of human immunodeficiency virus (HIV) prevention and treatment. The first 2, for the South Africa context, examined the value of long-acting, preexposure prophylaxis (LA-PrEP) for high-risk women 8 and a hypothetical HIV cure strategy. 9 The third considered the use of a generic version of efavirenz (EFV) as part of initial antiretroviral therapy (ART) in the US. 10 Costs and benefits for these case studies were grounded on recently published or conducted cost-effectiveness reports using the Cost-effectiveness of Preventing AIDS Complications (CEPAC) model, a complex patient-level microsimulation of HIV disease and treatment. [11] [12] [13] We begin by summarizing the general theoretical evaluation of EVPPI and EVSI. Then, we describe the practical calculation of EVPPI and EVSI using the conventional and alternative approaches. Next, we outline the 3 case studies used to illustrate the benefits of the alternative approach applied to the CEPAC model. Finally, we compare the EVPPI results between the 2 approaches, report the EVSI results from the alternative approach, and discuss the implications of our analysis.
Methods

Theoretical Evaluation of EVPPI and EVSI
Suppose we have a health economic model that, based on a set of uncertain parameters, u, estimates incremental net benefit, INB d, u ð Þ, for each of D different strategies (d = 1, . . . , D), such that d = 1 is the reference strategy (incremental net benefit of zero). The value of a decision made with current information is simply the maximum expected incremental net benefit across all strategies, where the expectation for each strategy is taken over the prior distribution of u (Table 1, Equation 1A ). For ease of comparison across the different approaches, all equations are presented in Table 1 .
First, we assume we can eliminate all uncertainty about a subset of the unknown parameters by carrying out a theoretical study that gives us perfect information. We refer to the subset of parameters for which information would be gained from this study as target parameters, denoted u T , and the other uncertain parameters that would not be measured in this study as complementary parameters, u C . As an example, we might learn the efficacy (u T ) of a drug in the study; however, the drug cost (u C ) would not be informed from the study and thus remains a complementary parameter. The value of a decision made with partial perfect information (perfect information about u T but not u C ) is the maximum expected incremental net benefit across strategies, where the expectation for each strategy is taken with respect to the conditional distribution of u given u T , denoted uju T . Since we do not yet know the true value of u T , we take the expectation of the maximized incremental net benefit over potential realizations of u T (Table 1, Equation 2A ). By definition, the EVPPI is the maximum price a decision maker should pay for additional perfect information on this subset of parameters. Mathematically, the EVPPI is the difference between the value of a decision made with partial perfect information and with current information (Table 1, Equation 3A ). Although obtaining perfect information is rarely possible, the EVPPI does provide an upper bound on the value that a real study could provide.
Study outcomes, X, collected from a finite sample size reduce, rather than entirely eliminate, the uncertainty about u T , with uncertainty reduced as the size of the study increases. The value of a decision made with sample information is the maximum expected incremental net benefit across strategies, where the expectation for each strategy is taken with respect to the conditional distribution of ujX . Again, as we have not yet observed these study outcomes, we average over potential realizations of X (Table 1, Equation 4A ). The EVSI is the difference between the value of a decision made with sample information and with current information (Table 1,  Equation 5A ). The EVSI is recalculated for each potential sample size and study design considered.
Conventional Approach to Estimating EVPPI and EVSI
The gold standard approach to EVPPI, developed by Ades and others, uses a nested Monte Carlo procedure. 
Value of decision made with PARTIAL PERFECT information
Value of decision made with SAMPLE information Although this nested procedure is not necessary for some simple cases (e.g., linear models), more complex models, such as the CEPAC model-which involves thousands of input parameters, non-linear relationships, and parameter interactions-require this more computationally intensive approach.
To implement the conventional nested Monte Carlo approach, we sample K realizations of the target parameters, and J sets of complementary parameters for each of the k = 1,.,K realizations of the target parameters, sampling the complementary parameters conditional on the target parameters. Each set of parameters is then used as input into the CEPAC model, resulting in N = J 3 K model evaluations for each strategy. The value of a decision made with current information is estimated by taking the maximum mean incremental net benefit across strategies (Table 1, Equation 1B ).
To estimate the value of a decision made with partial perfect information, we calculate the mean of the incremental net benefits across the J sets of complementary parameters for each set of target parameters, resulting in K mean incremental net benefit values for each of the D strategies. Then, for each k th set of values across strategies, we take the maximum, resulting in a single set of K maximum mean incremental net benefit values. The value of a decision made with partial perfect information is estimated by taking the mean of this set (Table 1,  Equation 2B ) and the conventional EVPPI is calculated as the difference (Table 1, Equation 3B ).
We provide the conventional equations for EVSI in Table 1 (Equations 4B and 5B). We did not calculate conventional EVSI in our analysis, as it was not feasible given the computational requirements of the CEPAC model. To calculate EVSI for a specific sample size, after drawing a sample u T , one would draw a hypothetical result for the study conditional on the value of u T , then update and draw from the conditional distribution, ujX k , based on the hypothetical result of the study.
Generalized Additive Model Approach
An alternative approach to the EVPPI or EVSI calculations developed by Strong and others 5 uses a generalized additive model 14 (GAM) to regress the simulation model-based incremental net benefits, obtained from probabilistic sensitivity analysis (PSA) results, on the target parameters (for EVPPI) or study outcomes (for EVSI). The expected value of the incremental net benefits is assumed to be some smooth function of the target parameters in the GAM approach. The GAM does not impose a specific functional form, but rather estimates the functional form as a part of the model fitting process. Any variation due to the complementary parameters is accounted for in the error term of the model. 5 This regression model can also include higher order terms, such as interactions between target parameters. In essence, a GAM is simply an extension of the multivariable linear regression model in which the linear form is replaced by a sum of unspecified smooth functions.
We obtain incremental net benefits for each strategy from the results of a standard PSA, which jointly samples M potential realizations of the target and complementary parameters and uses these realizations as input parameters in the CEPAC model. Following the algorithm outlined by Strong and others, we use a GAM to regress incremental net benefits on the target parameters and obtain the fitted values of incremental net benefit, denotedĝ m d, u T ð Þ for the m th fitted value obtained from the GAM of strategy d based on the entire set of target parameters, u T . Using these fitted values, the difference between a decision made with partial perfect information and with current information estimates the EVPPI (Table 1, Equation 3C ). Note that in Table 1 , Equation 3C, we estimate the value of the decision made with current information using fitted values obtained from the GAM, max d
since this leads to an increased precision of the EVPPI estimate due to a reduction in Monte Carlo sampling variability. 5 Estimating EVSI using the GAM approach is a 2-step process. In the first step, for each of the M iterations of the PSA, a study outcome (X m ) is simulated conditional on the target parameter value (u m T ) in that iteration. For example, for a target parameter of the probability of HIV virologic suppression of an HIV therapy at 48 weeks, the outcome is the number of participants in a study suppressed at 48 weeks. In the second step, we regress incremental net benefits on the study outcomes. We then obtain the fitted values and calculate the difference between the value of a decision made with sample information and with current information to estimate the EVSI (Table 1, Equation 5C ). For increased precision, we again estimate the value of a decision made with current information using the fitted values obtained from the GAM of the study outcomes X m , rather than those based on the PSA.
Case Studies
We chose 3 case studies to illustrate the results. Cases selected were CEPAC analyses, recently published [8] [9] [10] and are representative of ongoing HIV-related clinical trials or active fields of investigation. 15, 16 During the analysis of the EVSI results, we found interesting technical aspects unique to each case that highlight a spectrum of possible issues that might arise when using the GAM to estimate EVSI and therefore included all 3. The studies were assumed to update beliefs about target parameters but not to update beliefs about complementary parameters.
In the CEPAC model, individual patients are generated from random draws of user-defined cohort characteristics. The natural history of HIV disease progression is modeled as a series of monthly transitions between health states characterized by CD4 count (a marker of immune function) and HIV RNA viral load (which measures burden of HIV infection). Users also define HIV prevention or treatment strategies specific to the questions and setting of interest. Cost outcomes are generally assessed from the health system perspective. A more detailed technical specification of the CEPAC model is available at http://www.massgeneral.org/mpec/cepac/.
Case Study 1: LA-PrEP for High-risk South African Women. Standard oral pre-exposure prophylaxis (StdPrEP) is one of the few effective HIV prevention strategies currently available for high-risk South African women; however, its effectiveness is inherently linked to, and often limited by, daily pill adherence. [17] [18] [19] [20] [21] [22] [23] [24] Longacting injectable PrEP (LA-PrEP), currently under development in a Phase 2B/3 clinical trial, provides sustained drug levels, which could improve adherence and therefore effectiveness of PrEP. 25 A recent CEPAC analysis demonstrated that, even with an increased relative cost, LA-PrEP would prove cost-effective compared with Std-PrEP at its anticipated effectiveness benefit. 8 Since a placebo-controlled trial would be unethical, we considered the value of a 2-arm trial with 2-year follow-up to reduce the uncertainty of 2 target parameters: annual HIV incidence if LA-PrEP was implemented and annual HIV incidence if Std-PrEP was implemented. Complementary parameters included drug costs of LAPrEP and laboratory monitoring costs for the 2 strategies. Incremental net benefits were calculated with StdPrEP as the reference strategy using a primary willingness-to-pay threshold of $6,600/year of life saved (YLS), the 2014 South African per capita Gross Domestic Product (GDP). 26 Two alternative willingness-to-pay thresholds of $1,650/YLS and $19,800/YLS (25% and 300% of per capita GDP, respectively) were considered to examine the sensitivity of our results.
Case Study 2: A Hypothetical Cure Strategy in South Africa. Although the elimination of HIV from individuals has been demonstrated as possible based on a single case of HIV eradication using hematopoietic stem cell transplantation, 27 ongoing research is actively pursuing other more viable cure strategies. 16, 28, 29 We examined the performance benchmarks required for a hypothetical cure strategy to be a cost-effective alternative to the currently available antiretroviral therapy (ART) for the treatment of HIV infection by South African standards. 9 For this analysis, we examined the value of a single-arm, 2-year study among HIV patients with durable virologic suppression on ART to obtain estimates of 2 target parameters of a cure strategy: cure efficacy and monthly probability of relapse after cure. Complementary parameters included the cost of a cure strategy and the onetime probability of fatal toxicity related to a cure strategy. We assessed the value of a single-arm trial along the lines of a hypothetical cure strategy in this case study, so the study only updated beliefs about the cure strategy. Efficacy of the reference strategy, the currently available ART, was not updated by this study. Incremental net benefits were calculated with ART as the reference strategy and used the same willingness-to-pay thresholds as the first case study.
Case Study 3: Use of Generics for Efavirenz (EFV) in the US. In the US, at the time of this project, the current standard of care for first-line ART was most commonly a branded, single-pill, co-formulated regimen; e.g., tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/ efavirenz (EFV). With the anticipated approval of generic efavirenz (EFV) in the US, 30 decision makers would face the dilemma of whether and-even more importantly, what-to recommend for a switch to a multi-pill, generic-based regimen option. Thus, we compared the value of 2 hypothetical 2-arm trials, each with a 2-year follow-up: a 3-pill trial, comparing a 3-pill generic (generic EFV + generic lamivudine [3TC] + branded TDF) regimen to a single-pill branded (TDF/FTC/EFV) regimen, and a 2-pill trial, comparing a 2-pill generic (generic EFV + branded TDF/FTC) regimen to a single-pill branded regimen. For both studies, target parameters were the probabilities of 24-week HIV-RNA suppression and subsequent ART failure (after 24 weeks and through 96 weeks) specific to each strategy. Complementary parameters included mean CD4 cell count at ART initiation, costs of the generic drug components, monthly probability of lost to follow-up, and, upon being lost, the monthly probability of returning to care. Incremental net benefits (EVPPI and EVSI) were calculated assuming the frequently cited, US-based willingness-to-pay threshold of $100,000/YLS. [31] [32] [33] Again, 2 alternative willingness-to-pay thresholds of $25,000/YLS and $300,000/YLS were examined.
Parameter distributions for each case study can be found in Appendix Table 1 .
Computational and Statistical Methods for Value of Information Calculations
For the conventional approach, we used K = 5,000 realizations of the target parameters, J = 400 sets of complementary parameters, with 100,000 patients for each set of inputs, to estimate EVPPI using the conventional approach for each of our examples. This resulted in 2 3 10 11 (200 billion) patient lifetimes evaluated in the CEPAC per strategy. For EVSI, this procedure would be repeated for each sample size considered. The number of K and J simulations was pragmatic. A run with K = 1,000 realizations of the target parameters and J = 400 sets of complementary parameters required over a week to complete, and was used as they generally could be completed successfully. Larger runs tended to hit either storage capacity or time limits on the institutional research computing cluster. We recognize, however, that the relatively low number of sets of complementary parameters could lead to an upward bias in these calculations, but decided to accept this potential problem rather than make each of the projects even more computationally intensive. We combined the results from 5 separate runs to obtain the 5,000 realizations of the target parameters for each case study.
In contrast, when using the GAM approach, the 50,000 PSA simulations with 100,000 patients for each set of inputs required only 5 3 10 9 (5 billion) patient lifetime evaluations of the CEPAC model per strategy to evaluate EVPPI, 1/40th of the number of evaluations used in the conventional approach. Though there was no theoretical justification for the number of PSA simulations used, we selected 50,000 as a large, yet feasible, number. No additional evaluations were required to estimate EVSI for different sample sizes because EVSI uses the same PSA runs as the EVPPI estimation. Therefore, the only additional sampling needed was for the study outcomes that were calculated almost instantaneously.
For all 3 case studies, after calculating the mean net benefit for each strategy, we calculated the mean incremental net benefit for each non-reference strategy. For the conventional approach to EVPPI, we averaged over the J = 400 conditional complementary parameter values in each set and then averaged over the maximum incremental net benefit over the K = 5,000 realizations of the target parameters. For the GAM approach, we regressed incremental net benefits on the target parameters using the ''gam'' function within the R package ''mgcv'' (v 1.8-9). 34 The statistical analyses of the CEPAC results to obtain EVPPI and EVSI were performed using R version 3.2.2 (www.r-project.org) and conducted on a standard windows-based desktop computer.
To estimate EVSI, a single hypothetical study outcome was generated conditional on the target parameter drawn for each PSA iteration. This process was repeated for each study sample size of interest. As all target parameters were probabilities in our case studies, we assumed a binomial likelihood for data that are informative for the target parameters. Table 2 illustrates the process involved in determining the results for EVSI for a 2-arm study with a primary outcome of suppression, as in case study 3. This data simulation step was repeated for a range of hypothetical sample sizes to obtain the EVSI results for each case study.
Standard errors of the conventional EVPPI estimates were calculated by taking the standard deviation of 10,000 bootstrapped EVPPIs. For each iteration of the bootstrapping procedure, we sampled 5,000 incremental net benefit values with replacement and applied Equation 3B (Table 1) to calculate EVPPI. Standard errors of the GAM-based estimates were calculated by first drawing 1,000 sets of GAM coefficients from a multivariate normal distribution (using the coefficients and covariance matrix output from the GAM). We then applied the 1,000 new coefficients to the data from the PSA to obtain 1,000 new sets of fitted values (using the prediction matrix obtained from the GAM). Using these 1,000 sets of fitted values, we calculated 1,000 corresponding EVPPIs or EVSIs (using Equation 3C or 5C, respectively). The standard deviation of these results was used to estimate the standard error of the EVPPI/EVSI, as suggested by Strong and others. 5 GAM diagnostic plots were produced to ensure that modeling assumptions (and, thus, standard error estimates) were valid. First, partial residual plots-with the model-based component smooth functions overlaidwere used to assess whether the expectation of the incremental net benefits was a smooth function of the target parameters (EVPPI) or study outcomes (EVSI). Then, we plotted the fitted values against the GAM residuals and the simulated incremental net benefits to assess whether any unmodeled structure existed. For all 3 case studies, model diagnostics did not reveal any violations to the underlying assumptions for the final models used for the analysis.
We considered tensor-products between target parameters in the second and third case studies as we anticipated that there would be an interaction between parameters on incremental net benefit: such interactions are an inherent feature in the CEPAC model. Tensorproducts of terms treat the interaction as an additional bivariate smooth function in the GAM model. For example, in the second case study, if a cure strategy has a higher efficacy, then the relapse rate would have a more pronounced effect on the incremental net benefit than it would if there was low efficacy.
Results
Case Study 1: LA-PrEP for High-risk South African Women: Behavior and Precision across a Variety of Sample Sizes
Assuming a willingness-to-pay threshold of $6,600/YLS, the mean net benefit was $159,100/person for LA-PrEP and $157,800/person for Std-PrEP; the mean incremental net benefit of LA-PrEP was $1,300/person. Using the conventional Monte Carlo approach, we calculated the EVPPI of removing the uncertainty of the 2 efficacy target parameters to be $103/person. We obtained nearly the same estimate of EVPPI ($105/person) using the GAM approach (Table 3 , top). The conventional nested approach led to a relatively precise estimate of EVPPI (standard error $3); the GAM approach, however, led to even more precision, with standard errors \$1. As expected, EVSI estimates increased monotonically and approached EVPPI as the sample size increased from 25 to 50,000 patients per study arm (Table 3 , bottom). The increase in EVSI was drastic initially and then began to reach its asymptote for sample sizes above 5,000 patients per arm.
Case Study 2: A Hypothetical Cure Strategy in South Africa: Parameter Interactions and Nonlinear Functions
Assuming a willingness-to-pay threshold of $6,600/YLS, the mean net benefit was $116,300/person for the cure strategy and $114,100/person for the current ART strategy; the mean incremental net benefit of cure was $2,200/ person. The conventional approach estimated the EVPPI of cure efficacy and probability of relapse to be $151/person. The GAM approach gave the same value ($151, Table 3 , top). Again, the standard error of the GAM approach ($1) was smaller than the standard error of the conventional approach ($6). EVSI again increased monotonically and approached EVPPI as the sample size increased (Table 3, bottom). Although we draw for complementary parameters (column not shown), they are not specified in the table, as they are not involved in the GAM estimation of either EVPPI or EVSI; however, they are important for the estimation of incremental net benefit. This table illustrates the basic data setup for the GAM approach to EVPPI and EVSI. Both begin with a large number of PSA iterations, jointly sampling all uncertain parameters (both the target parameters of the study, u T , and the complementary parameters, u C ) and calculating the corresponding incremental net benefit values based on our patient-level simulation model. In our case studies, there were 50,000 iterations of the PSA. This illustration assumes a study estimating only the suppression rate in a control and experimental arm. Using the GAM approach, the value of a decision made with partial perfect information is estimated by the mean maximum value when incremental net benefits are predicted using a GAM based on the entire set of target parameters u T (Table 1, Equation 2C ). The value of a decision made with sample information is estimated as the mean maximum value when incremental net benefits are predicted using a GAM based on the entire set of study outcomes, X (Table 1, Equation 4C ). Figure 1 illustrates the inherent interaction between efficacy and relapse rate on the incremental net benefit in the CEPAC model. On the left, we stratified relapse rate into 2 equal sized groups: low relapse (bottom quartile of simulations) and high relapse (top quartile of simulations). As cure efficacy increased, the rate of increase in the incremental net benefit was faster (steeper positive slope) in simulations with low vs. high relapse. Intuitively, this reflects that the economic benefit of higher efficacy is enhanced when the relapse rate is lower. Figure 1 also demonstrates the flexible nature of the GAM approach, which was able to fit the non-linear relationship between cure relapse rate and incremental net benefit (Figure 1, right) .
Case Study 3: Use of Generics for EFV in the US: Scenario Limiting Pre-trial Decision to Non-optimal Reference Strategy Assuming a US-based willingness-to-pay threshold of $100,000/YLS, the mean net benefit was $981,400/person for the single-pill branded strategy, $1,010,200/person for the 2-pill generic strategy, and $1,022,700/person for the 3-pill generic strategy; the mean incremental net benefit was $28,800/person for the 2-pill v. the single-pill branded strategy and $41,300/person for the 3-pill v. the single-pill branded strategy. Using the conventional approach, we calculated the EVPPI for both hypothetical parallel group trials of generic EFV against SOC: $6,900/ person for the 2-pill trial and $5,500/person for the 3-pill trial scenarios. The GAM approach resulted in similar EVPPI estimates of $7,100/person for the 2-pill trial and $5,900/person for the 3-pill trial. Although the EVPPI estimate for the 3-pill trial obtained using the GAM approach was about 7% different from that obtained using the conventional approach, it was still within the confidence interval for the conventional Monte Carlo estimate. Again, the standard errors of the estimates were much larger for the conventional approach than for the GAM approach (Table 3 , top). EVSI increased monotonically and approached EVPPI as sample size increased. Similar to the relapse term in the second case study, the GAM approach identified a non-linear relationship between subsequent late ART failure and incremental net benefit (data not shown). Based on the relative value of the 2 trials, it would appear that the 2-pill trial offered the greater potential benefit than the 3-pill trial (e.g., $6,800/person vs. $5,600/person for the information gained from a study with 500 participants) ( Table 3) .
Using 2 alternative willingness-to-pay thresholds for each case study led to consistent EVPPI values (between conventional and GAM approach) and similar behavior and precision of EVSI (Appendix Table 2 ).
Analysis Time
Although we did not systematically record the computing requirements for the various case studies, the final analysis for the conventional approach to EVPPI took approximately 5 weeks per case study on an institutional-shared research computing cluster. Using the conventional approach would require a similar amount of computing time to calculate EVSI for each sample size considered. Once we obtained the results of the PSA runs (generated after 3 to 4 days per case study), no additional PSA runs were required for estimating EVPPI or EVSI across a range of sample sizes. The time to generate the study outcomes used in estimating the EVSI, fit the GAM to the study outcomes, and calculate the EVSI took less than 1 minute for all the sample sizes presented once the PSA results were available.
Discussion
The GAM approach facilitated EVSI calculation for 3 case studies using the CEPAC model, turning analyses that would have required months into ones that could be done in days. Compared to the conventional approach, this alternative method drastically reduced the number of evaluations of the CEPAC model, making EVSI calculations computationally feasible. We found that for EVPPI, the GAM approach and the conventional approach gave similar results (within 7%). The conventional approach was not feasible for EVSI. We also demonstrated the broad applicability of this method by including examples of non-linear functions and parameter interactions.
There has been a general call for applied examples and suggestions that this EVSI approach should be tested in more complex patient-level models. 5 We provide the first pragmatic application of this method to a complex patient-level model. The CEPAC model has thousands of input parameters, requiring weeks of computational Figure 1 Parameter interaction and non-linear function in case study 2: a hypothetical cure strategy in South Africa. The interaction between the 2 target parameters is shown by plotting each against incremental net benefit, colored by lower (light grey) and upper (dark grey) quartile of the other target parameter. For example, high monthly rate of cure relapse decreased the positive effect the efficacy of cure had on the incremental net benefit (i.e., shallower positive slope with high relapse; dark on left panel) compared with a low relapse rate (light on left panel). Conversely, high efficacy increased the negative effect of a higher monthly relapse rate on incremental net benefit (i.e., steeper negative slope with high efficacy; dark on right panel) compared with low efficacy (light on right panel). The right panel also demonstrates the non-linear relationship between cure relapse rate and incremental net benefit, especially for the high efficacy group, such that, as relapse increased, incremental net benefit decreased, but at a progressively slower rate. For clarity, only 5,000 randomly selected draws from the 50,000 PSA iterations are included.
runtime to calculate EVSI for a single trial and sample size, making the conventional approach to EVSI computationally infeasible. Moreover, with the CEPAC model, there is no closed form solution to the joint conditional parameter distribution, which created the need for a nested Monte Carlo procedure in the conventional approach; the GAM approach, however, required no closed form solution and a much more modest computational burden using standard PSA, which have become the norm in many health economic analyses. 35 It has been recommended that value of information research should investigate how this method will perform under different structural assumptions. 36 Previous applications of this method have considered only simple hypothetical economic models in which parameters are multi-linear and independent. We intentionally selected scenarios that contained non-linear functions between parameters and incremental net benefits as well as parameter interactions, and also compared the value of multiple trials to aid trial design. This analysis demonstrated that the GAM approach was able to adapt nicely to these structural irregularities.
The results of this analysis should be considered within the context of its limitations. First, there is no standard software available to calculate EVSI using this alternative GAM approach. To conduct this analysis, we expanded upon R code that has been previously developed for calculating EVPPI, so that it would also provide EVSI results; sample code for the first case study is in the Appendix. Second, although we have validated our EVPPI results, there is no gold standard by which to validate our EVSI estimates. We must rely on the face validity of our findings-that EVSI estimates initially increase rapidly as our sample size increases and then converge to EVPPI for larger samples. Third, others have proposed different alternatives to calculating EVSI; [2] [3] [4] [5] [6] [7] we focused on the GAM approach because of its flexibility in considering a non-linear functional form and in considering the interaction between terms (as highlighted in case study 2).
In our analysis of each case we were not exhaustive in the target parameters considered; we selected several important target parameters as a means of illustrating the viability of this approach. Thus, a more complete value of information analysis for each case might also include examination of other target parameters, unequal treatment allocations, and a more comprehensive consideration of additional (more than 2) intervention arms. Finally, we have estimated in this analysis the incremental net benefit for an individual. The next step to a complete value of information analysis-which would examine whether the overall anticipated benefit is worth
